Vertex Pharmaceuticals Incorporated growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +10.4%
EBITDA: +7165.1%
EBIT: +743.4%
EPS: +547.6%
Free cash flow: +394.9%
Operating cash flow: +532.6%

Forward estimates

Revenue: +10.6%
EBITDA: -9.3%
EPS: +19.0%

Three-year CAGR

Revenue: +10.6%
EBITDA: +3.1%
EBIT: +3.4%
Net income: +6.0%
EPS: +6.0%
Free cash flow: -6.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.